CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Uveitis Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Uveitis Treatment Market By Treatment Type
1.2.2.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Treatment Type (2015-2026)
1.2.2.2. Global Uveitis Treatment Market Revenue Share By Treatment Type in 2017
1.2.2.3. Monoclonal Antibodies
1.2.2.4. Cycloplegic Agents
1.2.2.5. Corticosteroids
1.2.2.6. Immunosuppressant
1.2.2.7. Antibiotics
1.2.2.8. Antifungal
1.2.2.9. Antivirals
1.2.2.10. Analgesics
1.2.3. Uveitis Treatment Market By Disease Type
1.2.3.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Disease Type (2015-2026)
1.2.3.2. Intermediate Uveitis
1.2.3.3. Posterior Uveitis
1.2.3.4. Anterior Uveitis
1.2.3.5. Panuveitis
1.2.4. Uveitis Treatment Market By Cause
1.2.4.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Cause (2015-2026)
1.2.4.2. Noninfectious
1.2.4.3. Infectious
1.2.5. Uveitis Treatment Market By Distribution Channel
1.2.5.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.5.2. Retail
1.2.5.3. Hospital
1.2.5.4. Online
1.2.6. Uveitis Treatment Market by Geography
1.2.6.1. Global Uveitis Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Uveitis Treatment Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Uveitis Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Uveitis Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Type of Global Uveitis Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Uveitis Treatment Major Manufacturers in 2017
CHAPTER 4. UVEITIS TREATMENT MARKET BY TREATMENT TYPE
4.1. Global Uveitis Treatment Revenue By Treatment Type
4.2. Monoclonal Antibodies
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Cycloplegic Agents
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Corticosteroids
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Immunosuppressant
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Antibiotics
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Antifungal
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Antivirals
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.9. Analgesics
4.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. UVEITIS TREATMENT MARKET BY DISEASE TYPE
5.1. Global Uveitis Treatment Revenue By Disease Type
5.2. Intermediate Uveitis
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Posterior Uveitis
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Anterior Uveitis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Panuveitis
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. UVEITIS TREATMENT MARKET BY CAUSE
6.1. Global Uveitis Treatment Revenue By Cause
6.2. Noninfectious
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Infectious
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. UVEITIS TREATMENT MARKET BY DISTRIBUTION CHANNEL
7.1. Global Uveitis Treatment Revenue By Distribution Channel
7.2. Retail
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Hospital
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Online
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. NORTH AMERICA UVEITIS TREATMENT MARKET BY COUNTRY
8.1. North America Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Uveitis Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Uveitis Treatment Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
8.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 9. EUROPE UVEITIS TREATMENT MARKET BY COUNTRY
9.1. Europe Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Uveitis Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.6.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
9.7.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 10. ASIA-PACIFIC UVEITIS TREATMENT MARKET BY COUNTRY
10.1. Asia-Pacific Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Uveitis Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 11. LATIN AMERICA UVEITIS TREATMENT MARKET BY COUNTRY
11.1. Latin America Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Uveitis Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 12. MIDDLE EAST UVEITIS TREATMENT MARKET BY COUNTRY
12.1. Middle East Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Uveitis Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 13. AFRICA UVEITIS TREATMENT MARKET BY COUNTRY
13.1. Africa Uveitis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Uveitis Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
13.3.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
13.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
13.4.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
13.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Disease Type, 2015 - 2026 ($Million)
13.5.3. Market Revenue and Forecast By Cause, 2015 - 2026 ($Million)
13.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 14. COMPANY PROFILE
14.1. Bausch & Lomb, Inc.
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Type Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Allergan, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Type Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. AbbVie, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Type Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Novartis AG
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Type Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Eyegate Pharmaceuticals, Inc.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Type Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Santen Pharmaceutical Co., Ltd
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Type Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. EyePoint Pharmaceuticals, Inc
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Type Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Others
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Type Portfolio
14.8.5. Key Developments
14.8.6. Strategies
CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope
According to Research study by Acumen Research and Consulting, the uveitis treatment market value is anticipated to be worth around US$ 860 million in 2026.
The uveitis treatment market is anticipated to grow over 5.5% CAGR during the forecast period 2019 to 2026.
Due to its nature as the main therapy for patients with noninfectious uveitis, corticosteroids had the greatest market share of 2018.
Due to a broad variety of alternatives for managing eye inflammation in hospitals, hospital pharmacies resulted the market in 2018 on a distribution channel.
Due to the increasing incidence of non-infectious uveitis in the US, North America resulted the market in 2018.
Asia Pacific, however, has been expected to display profitable CAGR over the prediction era primarily because of the increasing prevalence and absence of sanitation of infectious illnesses in the developing area.
Key players of uveitis treatment market include Bausch & Lomb, Inc.; Allergan, Inc.; AbbVie, Inc.; Novartis AG; Eyegate Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd; EyePoint Pharmaceuticals, Inc.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date